Myriad Genetics Future Growth
Future criteria checks 4/6
Myriad Genetics is forecast to grow earnings and revenue by 53.5% and 9.5% per annum respectively. EPS is expected to grow by 49.6% per annum. Return on equity is forecast to be -1.5% in 3 years.
Key information
53.5%
Earnings growth rate
49.6%
EPS growth rate
Biotechs earnings growth | 31.7% |
Revenue growth rate | 9.5% |
Future return on equity | -1.5% |
Analyst coverage | Good |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 787 | -42 | 28 | 45 | 6 |
12/31/2023 | 729 | -84 | 16 | 61 | 9 |
12/31/2022 | 673 | -86 | -131 | -126 | 9 |
9/30/2022 | 661 | -77 | -143 | -108 | N/A |
6/30/2022 | 672 | -18 | -165 | -146 | N/A |
3/31/2022 | 682 | -8 | -117 | -100 | N/A |
12/31/2021 | 691 | -27 | 0 | 18 | N/A |
9/30/2021 | 684 | -57 | -7 | 14 | N/A |
6/30/2021 | 662 | -97 | -26 | -6 | N/A |
3/31/2021 | 566 | -148 | 11 | 28 | N/A |
12/31/2020 | 557 | -224 | -40 | -27 | N/A |
9/30/2020 | 598 | -194 | -25 | -14 | N/A |
6/30/2020 | 639 | -199 | 51 | 61 | N/A |
3/31/2020 | 761 | -148 | 53 | 62 | N/A |
12/31/2019 | 813 | -26 | 43 | 52 | N/A |
9/30/2019 | 835 | -15 | 83 | 92 | N/A |
6/30/2019 | 851 | 5 | 75 | 84 | N/A |
3/31/2019 | 830 | 23 | 91 | 100 | N/A |
12/31/2018 | 796 | 26 | 96 | 105 | N/A |
9/30/2018 | 767 | 54 | 92 | 100 | N/A |
6/30/2018 | 744 | 133 | 108 | 116 | N/A |
3/31/2018 | 749 | 130 | 97 | 105 | N/A |
12/31/2017 | 763 | 126 | 128 | 134 | N/A |
9/30/2017 | 771 | 101 | 126 | 133 | N/A |
6/30/2017 | 729 | 17 | 100 | 106 | N/A |
3/31/2017 | 757 | 32 | 101 | 108 | N/A |
12/31/2016 | 751 | 63 | 106 | 113 | N/A |
9/30/2016 | 748 | 94 | 128 | 134 | N/A |
6/30/2016 | 741 | 117 | N/A | 166 | N/A |
3/31/2016 | 757 | 121 | N/A | 179 | N/A |
12/31/2015 | 747 | 108 | N/A | 163 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).
Earnings vs Market: MYD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYD is expected to become profitable in the next 3 years.
Revenue vs Market: MYD's revenue (9.5% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: MYD's revenue (9.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYD is forecast to be unprofitable in 3 years.